JP2022521801A - 多発性骨髄腫を治療するための方法 - Google Patents

多発性骨髄腫を治療するための方法 Download PDF

Info

Publication number
JP2022521801A
JP2022521801A JP2021550168A JP2021550168A JP2022521801A JP 2022521801 A JP2022521801 A JP 2022521801A JP 2021550168 A JP2021550168 A JP 2021550168A JP 2021550168 A JP2021550168 A JP 2021550168A JP 2022521801 A JP2022521801 A JP 2022521801A
Authority
JP
Japan
Prior art keywords
compound
multiple myeloma
subject
pharmaceutical composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021550168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521801A5 (enExample
Inventor
マーラ エル ウィートール
リャンシャン ツァオ
アーノルド ボロムスキー
ハインツ ルドヴィッヒ
Original Assignee
ピーティーシー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス， インコーポレイテッド filed Critical ピーティーシー セラピューティクス， インコーポレイテッド
Publication of JP2022521801A publication Critical patent/JP2022521801A/ja
Publication of JP2022521801A5 publication Critical patent/JP2022521801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021550168A 2019-02-28 2020-02-26 多発性骨髄腫を治療するための方法 Pending JP2022521801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812002P 2019-02-28 2019-02-28
US62/812,002 2019-02-28
PCT/US2020/019884 WO2020176610A1 (en) 2019-02-28 2020-02-26 Method for treating a multiple myeloma

Publications (2)

Publication Number Publication Date
JP2022521801A true JP2022521801A (ja) 2022-04-12
JP2022521801A5 JP2022521801A5 (enExample) 2023-03-02

Family

ID=72238680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550168A Pending JP2022521801A (ja) 2019-02-28 2020-02-26 多発性骨髄腫を治療するための方法

Country Status (11)

Country Link
US (1) US20220143016A1 (enExample)
EP (1) EP3931196A4 (enExample)
JP (1) JP2022521801A (enExample)
CN (1) CN113710670A (enExample)
AU (1) AU2020227748A1 (enExample)
BR (1) BR112021016747A2 (enExample)
CA (1) CA3131249A1 (enExample)
EA (1) EA202192117A1 (enExample)
IL (1) IL285800A (enExample)
MX (1) MX2021010398A (enExample)
WO (1) WO2020176610A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150315182A1 (en) * 2012-11-21 2015-11-05 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
EP2624818B1 (en) * 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Bortezomib formulations stabilised with boric acid
MX370588B (es) * 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
JP2021535198A (ja) * 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150315182A1 (en) * 2012-11-21 2015-11-05 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOLOMSKY A. ET AL.: "Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairsthe tumour microenviro", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 9, no. 17, JPN6024020064, 2016, pages 1 - 13, ISSN: 0005473048 *

Also Published As

Publication number Publication date
US20220143016A1 (en) 2022-05-12
WO2020176610A1 (en) 2020-09-03
EP3931196A4 (en) 2022-12-14
AU2020227748A1 (en) 2021-09-16
MX2021010398A (es) 2022-01-18
CN113710670A (zh) 2021-11-26
EA202192117A1 (ru) 2021-11-23
CA3131249A1 (en) 2020-09-03
EP3931196A1 (en) 2022-01-05
WO2020176610A8 (en) 2021-08-12
IL285800A (en) 2021-10-31
BR112021016747A2 (pt) 2021-10-19

Similar Documents

Publication Publication Date Title
KR20230059792A (ko) 암 치료를 위한 조합
JP2018513123A (ja) Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法
TW201536275A (zh) 藥物
JP2025032069A (ja) 膵臓癌を治療する方法
KR20170078811A (ko) 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법
RU2812782C2 (ru) Способ лечения острого миелоидного лейкоза
JP7602481B2 (ja) 肉腫を治療する方法に有用な組み合わせ
JP7428717B2 (ja) 急性骨髄性白血病の治療方法
US20220143016A1 (en) Method for treating a multiple myeloma
EA047152B1 (ru) Способ лечения множественной миеломы
Cui et al. Disulfiram alone regulates the radiosensitivity of lung cancer through NF-κB pathway and regulates the immune microenvironment after radiotherapy by targeting PD-L1 through c-Myc
EA046841B1 (ru) Комбинации, пригодные в способе лечения саркомы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241202